Summer Street chief scientific officer holds an analyst/industry conference call Chief Scientific Officer Classen discusses Aerie Pharmaceuticals' Roclatan for treatment of Glaucoma on an Analyst/Industry conference call to be held on June 12 at 11 am.
Aerie Pharmaceuticals pullback a buying opportunity, says Brean Capital Brean Capital analyst Difei Yang views the recent pullback in shares of Aerie Pharmaceuticals as a buying opportunity. After speaking to clients and company management, Yang sees no potential issues to warrant the recent selloff. The analyst points out that the company has more than $150M in cash, enough to support operations until 2017, making a capital raise very unlikely. Yang has a Buy rating on Aerie with a $48 price target.